The Morning Dose #160: Ashwagandha, GHK-Cu, And SLU-PP-332

Replace it. Insulin syringes with faded or unclear tick marks. Common in bulk-purchased syringes stored in high-humidity environments. Introduce systematic measurement error across every dose. Our team has reviewed this across hundreds of peptide research setups: unclear tick marks cause researchers to 'estimate' the position between visible lines, which introduces 10–20% dosage variance. Use syringes with sharply printed calibration lines and replace them if the markings degrade.

You won't harm the tissue, but you'll waste GHK-Cu. The peptide's collagen cross-linking mechanism requires newly deposited extracellular matrix to act on. Fibroblasts don't begin substantial collagen synthesis until days 3–5 post-injury in acute wounds. Administering GHK-Cu during the inflammatory phase means it clears before the proliferative cascade begins. Research shows no measurable benefit to GHK-Cu administration before day 4 in excisional wound models.

Four weeks is too early to assess structural remodeling. Collagen synthesis rates increase within days of starting GHK-Cu, but the accumulation of cross-linked fibers in the dermal layer takes 8–12 weeks to produce visible changes in fine line depth. Hydration and surface texture may improve sooner, but wrinkle reduction from net collagen gain requires a full collagen turnover cycle. Roughly 60–90 days in facial skin.

Formulation stability is the most common failure point. Copper peptides degrade rapidly in the presence of ascorbic acid (vitamin C) or at pH above 7.0. Check your product's ingredient list. If it contains L-ascorbic acid, alpha-tocopherol, or strong alkaline buffering agents, the GHK-Cu is likely inactive. Store the product in a cool, dark environment (refrigeration extends shelf life). If the formulation is sound and application is consistent, consider microneedling to enhance penetration. Topical delivery is inherently limited by stratum corneum barrier function.

The research supports a plausible mechanism for cartilage protection and anti-inflammatory effects, but clinical evidence for symptom relief in humans is limited to one small pilot trial. That trial showed 38% pain reduction versus placebo over eight weeks, which is meaningful but not definitive. If you're exploring GHK-Cu for osteoarthritis, approach it as an experimental compound with promising preclinical data. Not a proven therapy. Intra-articular delivery would be required, which means working with a physician willing to prepare and administer off-label peptide injections.